The World Health Organization announced on Monday that it would temporarily stop hydroxychloroquine trials due to reported safety concerns.
Hydroxychloroquine is an anti-malarial drug that has shown promise in the fight against the COVID-19 pandemic.
What are the details?
According to a Monday NBC News report, the embattled organization — which lost its U.S. funding over its mismanagement of the COVID-19 crisis — announced that the drug may cause potential dangers in patients and is choosing to “err on the side of caution” by temporarily ceasing trials.
The WHO has been under fire for several months after reportedly parroting China’s continued misinformations about COVID-19 and its origins.
WHO Director General Tedros Ghebreyesus said that evidence exists that hydroxychloroquine has reportedly shown dangerous side effects such as heart problems and more.
In a statement, Tedros said, “The executive group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity trial while the safety data is reviewed by the data safety monitoring board. The other arms of the trial are continuing.”
WHO chief scientist Dr. Soumya Swaminathan added that Tedros’ announcement jives with the organization’s investigations about the drug.
“So the steering committee met over the weekend and decided that in the light of this uncertainty that we should be proactive, err on the side of caution, and suspend enrollment, temporarily, into the hydroxychloroquine arm,” he said.
Last week, president Donald Trump announced that he had been taking hydroxychloroquine as a preventative measure against COVID-19.
“You’d be surprised at how many people are taking it — and especially the frontline workers, before you catch it — the frontline workers, many, many are taking it,” he said during a press conference. “I happen to be taking it.”
“I think it’s good, I’ve heard a lot of good stories. And if it’s not good, I’ll tell you right,” he continued. ” I’m not going to get hurt by it. It’s been around for 40 years for malaria, for lupus, for other things.”
Visit the USSA News store!
Click this link for the original source of this article.
Author: Sarah Taylor
This content is courtesy of, and owned and copyrighted by, http://theblaze.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu. The owner of this website may be paid to recommend American Bullion. The content of this website, including the positive review of American Bullion, the negative review of its competitors, and any other information may not be independent or neutral.